This report details the design and validation of EphA2‐targeting CAR‐NK cells for use against paediatric sarcomas using mRNA‐based transfection systems to transiently engineer hard‐to‐edit NK cells for therapeutic purposes. This evidence concerns the gene EPHA2 and sarcoma.